[CAS NO. 155148-31-5] Plerixaforoctahydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [155148-31-5]

Catalog

HY-50912

Brand

MCE

CAS

155148-31-5

DESCRIPTION [155148-31-5]

Overview

MDL	MFCD04974488
Molecular Weight	794.47
Molecular Formula	C28H62Cl8N8
SMILES	[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.N1(CCCNCCNCCCNCC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3

For research use only. We do not sell to patients.

49 Publications Citing Use of MCE

Summary

Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC ₅₀ of 44 nM.

IC50 & Target

¹²⁵ I-CXCL12-CXCR4

44 nM (IC ₅₀ )

¹²⁵ I-CXCL12-CXCR7

HIV-1

1-10 nM (EC ₅₀ )

HIV-2

1-10 nM (EC ₅₀ )

In Vitro

The CXCR4 inhibitor Plerixafor (AMD3100) is a potent inhibitor of CXCL12-mediated chemotaxis (IC ₅₀ , 5.7 nM) with a potency slightly better than its affinity for CXCR4. Treating the cells with CCX771 or CXCL11 has no effect on CXCL12-mediated MOLT-4 or U937 TEM. In contrast, 10 μM Plerixafor inhibits CXCL12-mediated TEM in both cells lines ^[1] . Plerixafor (10 μM)-treated cells show a moderate reduction in cell proliferation compared to CXCL12-stimulated cells, which do not reach statistical significance ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Plerixafor (2 mg/kg) administration to UUO mice exacerbates renal interstitial T cell infiltration, resulting in increased production of the pro-inflammatory cytokines IL-6 and IFN-γ and decreased expression of the anti-inflammatory cytokine IL-10 ^[3] . Both perivascular and interstitial fibrosis are significantly reduced by the CXCR4 antagonist, Plerixafor (AMD3100) at 8 weeks ^[4] . LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02703779	Siddhartha Ganguly\|University of Kansas Medical Center	Multiple Myeloma	March 2016	Phase 2
NCT02056210	University of Padova\|Azienda Ospedaliera di Padova	Diabetes	February 2014	Phase 4
NCT00967785	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Leukopenia\|Neutropenia\|Infections\|Warts\|Myelokathexis	January 6, 2010	Phase 1\|Phase 2
NCT01225419	University Hospital, Clermont-Ferrand	Children Cancer, Solid Tumor	September 2010	Phase 2
NCT03653247	Sangamo Therapeutics	Sickle Cell Disease	March 6, 2019	Phase 1\|Phase 2
NCT01042717	Shi, Patricia, M.D.\|Genzyme, a Sanofi Company	Multiple Myeloma\|Non-Hodgkins Lymphoma	February 2010	Not Applicable
NCT03240861	Jonsson Comprehensive Cancer Center\|California Institute for Regenerative Medicine (CIRM)	HLA-A*0201 Positive Cells Present\|Locally Advanced Malignant Neoplasm\|NY-ESO-1 Positive\|Unresectable Malignant Neoplasm\|Sarcoma	July 26, 2017	Phase 1
NCT02790957	Gian Paolo Fadini\|University Hospital Padova\|University of Padova	Diabetes\|Wounds\|Critical Limb Ischemia	June 2016	Phase 2
NCT01526096	University of Chicago	Myeloma	July 12, 2011	Phase 1
NCT01977677	Lawrence Recht\|National Cancer Institute (NCI)\|Stanford University	Adult Ependymoblastoma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Adult Medulloblastoma\|Adult Mixed Glioma\|Adult Oligodendroglial Tumors\|Adult Pineoblastoma\|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)	November 2014	Phase 1\|Phase 2
NCT01353937	NYU Langone Health\|National Institutes of Health (NIH)\|Genzyme, a Sanofi Company	Diabetic Ulcer	April 2014	Phase 1
NCT03157804	Hospital Infantil Universitario Niño Jesús, Madrid, Spain\|Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)\|Centro de Investigación en Red de Enfermedades Raras (CIBERER)\|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz\|Hospital Vall d´Hebron\|Universitat Autonoma de Barcelona	Fanconi Anemia	January 7, 2016	Phase 1\|Phase 2
NCT01206075	University of Washington\|National Heart, Lung, and Blood Institute (NHLBI)\|George Papanicolaou Hospital\|Genzyme, a Sanofi Company	Beta-Thalassemia	October 2010	Not Applicable
NCT02343666	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)\|National Heart, Lung, and Blood Institute (NHLBI)	Human Immunodeficiency Virus 1 Positive\|Stage I Adult Hodgkin Lymphoma\|Stage I Adult Non-Hodgkin Lymphoma\|Stage II Adult Hodgkin Lymphoma\|Stage II Adult Non-Hodgkin Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Non-Hodgkin Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Non-Hodgkin Lymphoma	August 15, 2016	Phase 1
NCT02678533	Assistance Publique - Hôpitaux de Paris\|EuroFancolen	Fanconi Anemia	February 10, 2017	Phase 1\|Phase 2
NCT01288573	Genzyme, a Sanofi Company\|Sanofi	Ewing´s Sarcoma+Soft Tissue Sarcoma\|Neuroblastoma\|Brain Tumors	March 3, 2014	Phase 1\|Phase 2
NCT00822770	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Stem Cell Transplantation\|Leukemia	January 2009	Phase 1\|Phase 2
NCT01339572	University of Florida	Non-Hodgkin´s Lymphoma\|Multiple Myeloma	April 2011	Phase 2
NCT02989701	Alessandra Biffi\|Boston Children´s Hospital	Sickle Cell Disease Without Crisis	January 2017	Phase 1
NCT02231879	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Myelokathexis\|Infections\|Neutropenia\|Warts\|Hypogammaglobulinemia	October 14, 2014	Phase 2\|Phase 3
NCT01146834	Weill Medical College of Cornell University\|Millennium Pharmaceuticals, Inc.	Multiple Myeloma	March 2011	Phase 3
NCT00445302	Genzyme, a Sanofi Company\|Sanofi	Renal Impairment	January 2006	Phase 1
NCT00322127	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy Volunteers	June 14, 2006	Phase 1
NCT01916577	University of Colorado, Denver\|Sanofi	COPD\|Cystic Fibrosis\|Pulmonary Fibrosis	August 2013	Phase 1
NCT00322491	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	March 2004	Phase 2
NCT04045821	Reproductive Medicine Associates of New Jersey	Infertility of Uterine Origin	January 17, 2020	Not Applicable
NCT01319864	Seattle Children´s Hospital\|Children´s Healthcare of Atlanta\|Pediatric Oncology Experimental Therapeutics Investigation Consortium	Relapsed+Refractory AML\|Relapsed+Refractory ALL\|Secondary AML+MDS\|Acute Leukemia of Ambiguous Lineage\|AML\|ALL	March 2011	Phase 1
NCT00914849	Washington University School of Medicine	Hematologic Neoplasms	August 2009	Phase 2
NCT02179970	CCTU- Cancer Theme\|Sanofi\|Stand Up To Cancer\|CRUK Cambridge Institute\|Lustgarten Foundation\|National Institute for Health Research, United Kingdom\|Cambridge University Hospitals NHS Foundation Trust	Pancreatic Adenocarcinoma Metastatic\|Ovarian Serous Adenocarcinoma\|Colorectal Cancer Metastatic	June 2015	Phase 1
NCT01280955	Mitchell Horwitz, MD\|Genzyme, a Sanofi Company\|Duke University	Failure of Bone Marrow Graft	December 2011	Phase 1\|Phase 2
NCT01818284	M.D. Anderson Cancer Center\|Proteonomix, Inc.	Blood And Marrow Transplantation	October 2013	Phase 2
NCT01547806	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Plasma Cell Myeloma\|Multiple Myeloma	February 22, 2012	Phase 2
NCT01097057	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Non-Hodgkin Lymphoma	November 9, 2010	Phase 2
NCT02193191	Memorial Sloan Kettering Cancer Center\|Sanofi\|New York Blood Center\|Weill Medical College of Cornell University\|Duke University	Sickle Cell Disease	September 2014	Phase 1
NCT01186224	University of Liverpool\|Genzyme, a Sanofi Company	Multiple Myeloma\|Plasma Cell Dyscrasia\|Lymphoma\|Lymphoproliferative Disorders	May 2010	Not Applicable
NCT02682953	University of Maryland, Baltimore\|Healogics	Bone Marrow Transplantation\|Hematopoietic Stem Cells\|Multiple Myeloma\|Lymphoma	October 2015	Phase 2
NCT03277209	Weill Medical College of Cornell University\|Cambridge University Hospitals NHS Foundation Trust	Pancreas Cancer	July 25, 2017	Phase 1
NCT00669669	Fred Hutchinson Cancer Center	Glioblastoma\|Gliosarcoma	February 25, 2009	Phase 1\|Phase 2
NCT01301963	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Refractory Multiple Myeloma	July 2011	Phase 3
NCT02212535	Assistance Publique - Hôpitaux de Paris	Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia	January 15, 2016	Phase 1\|Phase 2
NCT02931071	Hospital Universitari Vall d´Hebron Research Institute\|CIEMAT\|CIBERER	Fanconi Anemia	September 2013	Phase 2
NCT02006225	Tel-Aviv Sourasky Medical Center\|Sanofi	Autologous Stem Cell Transplantation	February 2014	Phase 4
NCT01753453	Sanofi\|Genzyme, a Sanofi Company	Multiple Myeloma	June 2013	Phase 2
NCT00998049	Mayo Clinic	Multiple Myeloma\|Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	December 2009	Phase 2
NCT01331018	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)\|Rocket Pharma Limited	Fanconi Anemia	February 22, 2012	Phase 1
NCT00943943	M.D. Anderson Cancer Center\|Bayer\|Genzyme, a Sanofi Company\|Amgen\|National Cancer Institute (NCI)\|Georgia Institute of Technology	Acute Myelogenous Leukemia\|Leukemia	October 29, 2010	Phase 1
NCT04058145	Massachusetts General Hospital\|Merck Sharp & Dohme LLC\|AperiSys, Inc	Head and Neck Cancer	September 30, 2019	Phase 2
NCT00322842	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	September 2004	Phase 2
NCT01160354	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Acute Myelogenous Leukemia	August 2010	Phase 1\|Phase 2
NCT03547830	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Chronic Granulomatous Disease	April 13, 2019	Phase 2
NCT00322387	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Non-Hodgkin\|Multiple Myeloma	April 2004	Phase 2
NCT02221492	Genzyme, a Sanofi Company\|Sanofi	Lymphoma	November 2014	Phase 2
NCT05343572	Hugh Taylor\|Yale University	Asherman Syndrome\|Atrophic Endometrium\|Recurrent Implantation Failure	September 2022	Early Phase 1
NCT01373229	David Rizzieri, MD\|Celgene Corporation\|Genzyme, a Sanofi Company\|Duke University	Leukemia, Lymphocytic, Chronic, B-Cell	January 2012	Phase 1
NCT05007652	Kyowa Kirin Co., Ltd.	Multiple Myeloma and Malignant Lymphoma	August 10, 2021	Phase 2
NCT01579149	Genzyme, a Sanofi Company\|Sanofi	Healthy Volunteer	September 2011	Phase 1
NCT01026987	Washington University School of Medicine	Stem Cell Transplant Patients	April 29, 2010	Phase 1
NCT01164345	Sheba Medical Center	Non-Hodgkin´s Lymphoma\|Hodgkin´s Lymphoma\|Stem Cell Mobilization\|Autologous Stem Cell Transplantation	June 2010	Phase 2
NCT04817345	St. Jude Children´s Research Hospital\|Doris Duke Charitable Foundation	Sickle Cell Disease	November 2022	Phase 2
NCT01954914	Technische Universität Dresden\|University Hospital Carl Gustav Carus\|Cellex Gesellschaft für Zellgewinnung mbH Dresden\|Cellex Gesellschaft für Zellgewinnung mbH Köln	Blood Stem Cell Harvest Failure	December 2013	Phase 2
NCT01068301	St. Jude Children´s Research Hospital\|Genzyme, a Sanofi Company	Acute Lymphoblastic Leukemia\|Acute Myeloid Leukemia\|Chronic Myeloid Leukemia\|Myelodysplastic Syndrome\|Non-Hodgkin´s Lymphoma	May 2010	Phase 1
NCT00082329	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy	June 18, 2004	Phase 2
NCT05087212	Sanofi	Autologous Haematopoietic Stem Cell Transplant	October 22, 2021	Phase 4
NCT01076270	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|de Novo Myelodysplastic Syndromes\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Burkitt Lymphoma\|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma\|Noncontiguous Stage II Adult Lymphoblastic Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Grade 3 Follicular Lymphoma\|Noncontiguous Stage II Mantle Cell Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes\|Splenic Marginal Zone Lymphoma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Chronic Lymphocytic Leukemia\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Multiple Myeloma\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Small Lymphocytic Lymphoma	June 2010	Not Applicable
NCT03055247	IRCCS San Raffaele\|Fondazione Telethon	Chronic Granulomatous Disease X-linked (X-CGD)	November 6, 2015	Phase 2
NCT01621477	St. Jude Children´s Research Hospital\|Assisi Foundation	Acute Lymphoblastic Leukemia\|Acute Myelocytic Leukemia\|Chronic Myelocytic Leukemia\|Juvenile Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Hodgkin or Non-Hodgkin Lymphoma\|Sarcoma, Myeloid	August 2012	Phase 2
NCT05088356	Stanford University\|Orca Biosystems, Inc.	Allogeneic Hematopoietic Cell Transplantation (HCT)\|Advanced Hematologic Malignancies\|Acute Leukemia\|Chronic Myelogenous Leukemia\|Myelodysplastic Syndromes\|Myeloproliferative Disorders	September 7, 2021	Phase 1
NCT04177810	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Genzyme, a Sanofi Company\|American Association for Cancer Research\|National Cancer Institute (NCI)	Metastatic Pancreatic Cancer	November 16, 2020	Phase 2
NCT00444912	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin Lymphoma\|Hodgkin Disease	February 2006	Phase 2
NCT01408043	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Adult Acute Lymphoblastic Leukemia in Remission\|Adult Grade III Lymphomatoid Granulomatosis\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	October 2011	Not Applicable
NCT00241358	Washington University School of Medicine	Leukemia, Myeloid, Acute\|Leukemia, Myelogenous, Chronic\|Leukemia, Lymphoblastic, Acute\|Lymphocytic Leukemia, Chronic\|Myelodysplastic Syndromes\|Multiple Myeloma\|Lymphoma, Non-Hodgkin\|Hodgkin Disease	May 2004	Phase 1\|Phase 2
NCT01352650	Weill Medical College of Cornell University\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	June 17, 2011	Phase 1
NCT01767714	Sanofi	Non-Hodgkin´s Lymphoma	April 2013	Phase 3
NCT00741780	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Autologous Transplantation	June 2006
NCT03406091	Fondazione EMN Italy Onlus	Multiple Myeloma	November 26, 2015
NCT04762875	Magenta Therapeutics, Inc.\|National Marrow Donor Program	Related Donors Donating PBSC to a Family Member\|Healthy Donors\|Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome	June 16, 2021	Phase 2
NCT01220375	University Hospital Inselspital, Berne	Myeloma	April 2010	Phase 2
NCT01655875	Emory University	Pediatric Acute Myeloblastic Leukemia, Relapsed\|Pediatric Acute Lymphoblastic Leukemia, Relapsed	June 2012	Phase 1
NCT00720603	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Multiple Myeloma
NCT01141543	University Health Network, Toronto\|Princess Margaret Hospital, Canada	Acute Myeloid Leukemia	May 2010
NCT05470491	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	HIV\|Hematologic Malignancies	November 27, 2022	Phase 1\|Phase 2
NCT00395967	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Lymphoma, Non-Hodgkin´s	April 2005	Phase 2
NCT00396383	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Multiple Myeloma	November 2004	Phase 2
NCT01149863	Emory University\|Genzyme, a Sanofi Company	Autologous Transplantation	June 2010	Phase 2
NCT03244930	Hospital Universitario Dr. Jose E. Gonzalez	Lymphoma, Non-Hodgkin\|Lymphoma, Hodgkin\|Myeloma\|Stem Cell Transplant Complications	May 10, 2017	Phase 2
NCT03182426	University of Alberta\|Alberta Innovates Health Solutions	Diabetes Mellitus, Type 1	August 15, 2017	Phase 1\|Phase 2
NCT00075335	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Healthy	January 2004	Phase 2
NCT02200380	Celldex Therapeutics	For Donors\|Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling\|For Recipients\|Acute Myelogenous Leukemia (AML)\|Acute Lymphoblastic Leukemia (ALL)\|Myelodysplastic Syndrome (MDS)\|Chronic Myelogenous Leukemia (CML)\|Non-Hodgkins Lymphoma (NHL)\|Hodgkins Disease (HD)\|Chronic Lymphocytic Leukemia (CLL)	July 2014	Phase 2
NCT01696461	Center for International Blood and Marrow Transplant Research\|Genzyme, a Sanofi Company\|Sanofi	Related Donors Donating PBSC to a Family Member\|Acute Myelogenous Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome\|Chronic Myelogenous Leukemia\|Non-Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Chronic Lymphocytic Leukemia	May 2013	Phase 2
NCT00396968	Genzyme, a Sanofi Company\|AnorMED\|Sanofi	Acute Myelogenous Leukemia\|Myelodysplastic Syndromes		Phase 1\|Phase 2
NCT02221479	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma	October 2014	Phase 2
NCT03612466	Albert Einstein College of Medicine\|National Cancer Institute (NCI)	Osteosarcoma\|Bone Metastases	August 2022	Phase 1
NCT01027923	Washington University School of Medicine	Leukemia, Myeloid, Acute	May 2010	Phase 1
NCT00838357	Genzyme, a Sanofi Company\|Sanofi	Lymphoma (Non-Hodgkin´s Lymphoma)\|Hodgkin´s Disease or Multiple Myeloma\|Front Line Mobilization\|Transplantation	September 2008	Phase 3
NCT00396331	Genzyme, a Sanofi Company\|Sanofi	Autologous Stem Cell Transplantation	October 2005	Phase 2
NCT01413100	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Systemic Scleroderma	September 15, 2011	Phase 2
NCT01318317	City of Hope Medical Center\|National Cancer Institute (NCI)	Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Non-Hodgkin Lymphoma	September 19, 2011	Phase 1\|Phase 2
NCT00990054	Genzyme, a Sanofi Company\|Sanofi	Acute Myeloid Leukemia	December 2009	Phase 1
NCT00291811	Genzyme, a Sanofi Company\|Sanofi	Autologous Stem Cell Transplant	October 2003
NCT01236144	Cardiff University\|Leukaemia & Lymphoma Research Group\|Experimental Cancer Medicine Centres	Acute Myeloid Leukaemia\|High Risk Myelodysplastic Syndrome	April 2011	Phase 1\|Phase 2
NCT03019809	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	Wiskott-Aldrich Syndrome\|Hematopoietic Stem Cell Transplantation\|Graft Failure	June 2016	Phase 2
NCT00694590	Genzyme, a Sanofi Company\|Sanofi	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	June 2008	Phase 1
NCT01339039	Patrick Y. Wen, MD\|Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Genzyme, a Sanofi Company	High Grade Glioma: Glioblastoma (GBM)\|High Grade Glioma: Gliosarcoma\|Anaplastic Astrocytoma (AA)\|Anaplastic Oligodendroglioma (AO)\|Mixed Anaplastic Oligoastrocytoma (AOA)	December 2011	Phase 1
NCT00903968	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Genzyme, a Sanofi Company\|Millennium Pharmaceuticals, Inc.	Multiple Myeloma	June 1, 2009	Phase 1\|Phase 2
NCT01164475	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma	October 2010	Phase 4
NCT01435343	PETHEMA Foundation	Acute Myeloblastic Leukemia	July 2012	Phase 1\|Phase 2
NCT02522572	E. Steve Woodle\|Sanofi-Synthelabo\|University of Cincinnati	Transplants and Implants	August 2015	Phase 1\|Phase 2
NCT05411575	4Living Biotech\|4P-Pharma	COVID-19 Acute Respiratory Distress Syndrome\|COVID-19	July 19, 2022	Phase 2
NCT03226691	National Heart, Lung, and Blood Institute (NHLBI)\|St. Jude Children´s Research Hospital\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease	July 25, 2017	Phase 1
NCT00479115	Children´s Hospital Medical Center, Cincinnati\|National Heart, Lung, and Blood Institute (NHLBI)	Fanconi Anemia	May 2007	Phase 1\|Phase 2
NCT03506802	Jonsson Comprehensive Cancer Center\|Novartis Pharmaceuticals	HLA-A*0201 Positive Cells Present\|NY-ESO-1 Positive Tumor Cells Present\|Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	July 10, 2018	Phase 1
NCT00901225	Duke University\|Genzyme, a Sanofi Company	Multiple Myeloma\|Non-Hodgkins Lymphoma\|Hodgkins Disease	May 2009	Phase 2
NCT03664830	City of Hope Medical Center	Sickle Cell Disease	September 19, 2018	Phase 1
NCT05445128	Magenta Therapeutics, Inc.\|bluebird bio	Sickle Cell Disease	June 24, 2022	Phase 2
NCT03746080	Lawrence D Recht\|Sanofi\|Stanford University	Glioblastoma\|Glioblastoma With Primitive Neuronal Component\|Gliosarcoma\|Malignant Glioma\|Oligodendroglial Component Present	December 4, 2018	Phase 2
NCT02015013	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Idiopathic CD4-Positive\|T-Lymphocytopenia	January 15, 2014	Phase 2
NCT01455025	French Innovative Leukemia Organisation\|Acute Leukemia French Association\|Genzyme, a Sanofi Company	Acute Myeloid Leukemia	January 2012	Phase 1
NCT01158118	Washington University School of Medicine	Leukemia, Myeloid, Acute\|Myelodysplastic Syndromes\|Lymphoma, Non-Hodgkin\|Hodgkin Disease\|Leukemia, Lymphocytic, Chronic, B-Cell\|Multiple Myeloma	April 1, 2011	Phase 2
NCT00512252	Washington University School of Medicine	Leukemia, Myeloid, Acute	July 2007	Phase 1\|Phase 2
NCT01403896	Stephen Couban\|Genzyme, a Sanofi Company\|Nova Scotia Health Authority	Malignant Lymphoma, Stem Cell Type	April 2012	Phase 2
NCT01711073	Proteonomix, Inc.\|University of Medicine and Dentistry of New Jersey\|Numoda	End Stage Liver DIsease	October 2012	Phase 1
NCT01074060	City of Hope Medical Center	Refractory Multiple Myeloma\|Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	April 2010	Phase 1
NCT00665314	Genzyme, a Sanofi Company\|Sanofi	Lymphoma\|Non Hodgkin´s Lymphoma\|Hodgkin´s Disease\|Multiple Myeloma	November 2007	Phase 2
NCT00741325	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma\|Autologous Transplantation	June 2006
NCT00733824	Washington University School of Medicine	Lymphoma, Non-Hodgkin\|Hodgkin Disease	November 2008	Phase 1\|Phase 2
NCT01738373	Genzyme, a Sanofi Company\|Sanofi	Bone Marrow + Autologous Transplants	December 2011
NCT02570542	Memorial Sloan Kettering Cancer Center\|Columbia University\|NorthShore University HealthSystem\|University of Rochester\|Medical College of Wisconsin\|University of Nebraska\|Sanofi\|University Hospitals Seidman Cancer Center	Diffuse Large B-cell Lymphoma (DLBCL)\|Relapsed Diffuse Large B-cell Lymphoma (DLBCL)\|Refractory Diffuse Large B-cell Lymphoma (DLBCL)	October 2015	Phase 2
NCT00906945	Washington University School of Medicine	Leukemia, Myeloid, Acute	February 2011	Phase 1\|Phase 2
NCT04552743	Surbhi Sidana, MD\|Stanford University	Multiple Myeloma	October 5, 2020	Phase 2
NCT02098109	Washington University School of Medicine	Multiple Myeloma\|Lymphoma, Non-Hodgkin	August 20, 2014	Phase 2
NCT00396266	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma\|Lymphoma, Non-Hodgkin	January 2005	Phase 2
NCT01610999	Tufts Medical Center	Chronic Lymphocytic Leukemia\|Lymphoma\|Multiple Myeloma	July 2013	Phase 1
NCT01095757	Emory University\|Genzyme, a Sanofi Company	Myeloma\|Lymphoma	March 2010	Phase 2
NCT03932864	Magenta Therapeutics, Inc.	Healthy Volunteers	April 22, 2019	Phase 1
NCT05357482	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia\|Beta Thalassemia	May 12, 2022	Phase 1\|Phase 2
NCT01700608	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Lymphoma\|Myeloma	September 2008
NCT01037517	CancerCare Manitoba	Multiple Myeloma\|Lymphoma	January 2010	Phase 2
NCT01058993	University of Washington	Neutropenia	October 2010	Phase 1
NCT01746173	Dana-Farber Cancer Institute\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center	T-cell Non-Hodgkin Lymphoma	July 2013	Phase 2
NCT00103610	Genzyme, a Sanofi Company\|Sanofi	Lymphoma, Non-Hodgkin	January 2005	Phase 3
NCT01802892	GlaxoSmithKline	Transplantation, Stem Cell	November 2, 2012	Phase 1
NCT00103662	Genzyme, a Sanofi Company\|Sanofi	Multiple Myeloma	January 2005	Phase 3
NCT01065129	Washington University School of Medicine	Myelodysplastic Syndromes	September 2, 2010	Phase 1
NCT00396201	Genzyme, a Sanofi Company\|Sanofi	Hodgkin´s Disease	November 2004	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 100 mg/mL ( 125.87 mM ; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2587 mL	6.2935 mL	12.5870 mL
5 mM	0.2517 mL	1.2587 mL	2.5174 mL
10 mM	0.1259 mL	0.6294 mL	1.2587 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 120 mg/mL (151.04 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

1,4,8,11-Tetraazacyclotetradecane, 1,1′-[1,4-phenylenebis(methylene)]bis-, hydrochloride (1:8)

1,4,8,11-Tetraazacyclotetradecane, 1,1′-[1,4-phenylenebis(methylene)]bis-, octahydrochloride

1,1′-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] hydrochloride (1:8)

JM 3100

SID 791

AMD 3100

Plerixafore 8HCl

AMD 3100 octahydrochloride